Amedisys Stock Piotroski F Score
| AMED Stock | USD 90.78 0.18 0.20% |
Amedisys | Piotroski F Score |
At this time, it appears that Amedisys' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
6.0
Piotroski F Score - Healthy
| Current Return On Assets | Negative |
| Change in Return on Assets | Increased |
| Cash Flow Return on Assets | Positive |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Increase |
| Current Ratio Change | Increase |
| Long Term Debt Over Assets Change | Higher Leverage |
| Change In Outstending Shares | Decrease |
| Change in Gross Margin | No Change |
Amedisys Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Amedisys is to make sure Amedisys is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Amedisys' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Amedisys' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 2.01 | 1.0855 |
|
| |||||
| Gross Profit Margin | 0.19 | 0.2044 |
|
| |||||
| Total Current Liabilities | 497.4 M | 473.7 M |
|
| |||||
| Non Current Liabilities Total | 490 M | 466.7 M |
|
| |||||
| Total Assets | 2.2 B | 2.1 B |
|
| |||||
| Total Current Assets | 521.8 M | 496.9 M |
|
|
Amedisys F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Amedisys' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Amedisys in a much-optimized way.
Click cells to compare fundamentals
About Amedisys Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
About Amedisys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Amedisys's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Amedisys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Amedisys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Amedisys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.Moving together with Amedisys Stock
| 0.91 | EMBC | Embecta Corp Financial Report 10th of May 2024 | PairCorr |
Moving against Amedisys Stock
| 0.77 | HIMS | Hims Hers Health Financial Report 13th of May 2024 | PairCorr |
| 0.66 | ELMD | Electromed | PairCorr |
| 0.54 | HOLX | Hologic Financial Report 6th of May 2024 | PairCorr |
| 0.53 | BAX | Baxter International Financial Report 25th of April 2024 | PairCorr |
| 0.51 | ALC | Alcon AG Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.
The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Amedisys Altman Z Score, Amedisys Correlation, Amedisys Valuation, as well as analyze Amedisys Alpha and Beta and Amedisys Hype Analysis. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.30) | Revenue Per Share 68.603 | Quarterly Revenue Growth 0.016 | Return On Assets 0.0598 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.